Seeking Alpha
Value, growth, long-term horizon, medium-term horizon
Profile| Send Message| ()  

Do you like to invest with a stock's momentum trends? With this idea in mind, we ran a screen.

We began by screening for stocks trading under $5 a share for those with positive market sentiment, rallying above their 20-day, 50-day, and 200-day moving averages.

We then screened for those with bullish sentiment from institutional investors, with significant net institutional purchases over the last quarter representing at least 5% of share float. This indicates that institutional investors such as hedge fund managers and mutual fund managers expect these names to outperform into the future.

For an interactive version of this chart, click on the image below. Analyst ratings sourced from Zacks Investment Research.

Tool provided by Kapitall.

Do you think these stocks will continue to rally higher? Use this list as a starting point for your own analysis.

List sorted by net institutional purchases as a percent of share float.

1. Celldex Therapeutics, Inc. (CLDX): Engages in the development, manufacture, and commercialization of targeted immunotherapies that prevent or treat specific forms of cancer, autoimmune disorders, and diseases caused by infectious organisms. Market cap at $251.99M, most recent closing price at $4.29. The stock is currently trading 1.29% above its 20-day moving average, 0.73% above its 50-day MA, and 18.94% above its 200-day MA. Net institutional purchases in the current quarter at 11.8M shares, which represents about 20.16% of the company's float of 58.53M shares.

2. YM BioSciences Inc. (YMI): Engages in the licensing and commercialization of drug products and technologies primarily for the treatment of cancer or cancer-related conditions worldwide. Market cap at $295.31M, most recent closing price at $1.88. The stock is currently trading 0.63% above its 20-day moving average, 7.50% above its 50-day MA, and 9.85% above its 200-day MA. Net institutional purchases in the current quarter at 25.5M shares, which represents about 18.65% of the company's float of 136.72M shares.

3. Orexigen Therapeutics, Inc. (OREX): Focuses on the development of pharmaceutical product candidates for the treatment of obesity. Market cap at $261.63M, most recent closing price at $3.86. The stock is currently trading 14.95% above its 20-day moving average, 8.85% above its 50-day MA, and 42.72% above its 200-day MA. Net institutional purchases in the current quarter at 9.8M shares, which represents about 16.28% of the company's float of 60.18M shares.

4. Corcept Therapeutics Incorporated (CORT): Engages in the discovery and development of drugs for the treatment of severe metabolic and psychiatric disorders. Market cap at $370.47M, most recent closing price at $4.18. The stock is currently trading 2.51% above its 20-day moving average, 7.43% above its 50-day MA, and 19.88% above its 200-day MA. Net institutional purchases in the current quarter at 5.5M shares, which represents about 10.99% of the company's float of 50.04M shares.

5. BioCryst Pharmaceuticals, Inc. (BCRX): Designs, optimizes, and develops small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, cancer, and inflammatory diseases. Market cap at $179.47M, most recent closing price at $3.65. The stock is currently trading 9.58% above its 20-day moving average, 0.02% above its 50-day MA, and 6.27% above its 200-day MA. Net institutional purchases in the current quarter at 4.4M shares, which represents about 10.43% of the company's float of 42.17M shares.

6. Glu Mobile, Inc. (GLUU): Engages in the design, marketing, and sale of casual and traditional mobile games worldwide. Market cap at $301.86M, most recent closing price at $4.68. The stock is currently trading 1.97% above its 20-day moving average, 2.26% above its 50-day MA, and 24.85% above its 200-day MA. Net institutional purchases in the current quarter at 4.6M shares, which represents about 8.73% of the company's float of 52.71M shares.

7. China XD Plastics Company Ltd. (CXDC): Through its subsidiary, Harbin Xinda Macromolecule Material Co. Market cap at $228.62M, most recent closing price at $4.81. The stock is currently trading 2.79% above its 20-day moving average, 1.13% above its 50-day MA, and 0.52% above its 200-day MA. Net institutional purchases in the current quarter at 1.1M shares, which represents about 7.37% of the company's float of 14.93M shares.

8. Avanir Pharmaceuticals (AVNR): Engages on acquiring, developing, and commercializing novel therapeutic products for the treatment of central nervous system disorders primarily in the United States. Market cap at $397.54M, most recent closing price at $2.93. The stock is currently trading 6.36% above its 20-day moving average, 3.83% above its 50-day MA, and 8.51% above its 200-day MA. Net institutional purchases in the current quarter at 8.8M shares, which represents about 6.56% of the company's float of 134.12M shares.

9. Lexicon Pharmaceuticals, Inc. (LXRX): Focuses on the discovery and development of drug candidates for the treatment of various human diseases. Market cap at $922.87M, most recent closing price at $1.92. The stock is currently trading 15.25% above its 20-day moving average, 18.47% above its 50-day MA, and 35.71% above its 200-day MA. Net institutional purchases in the current quarter at 10.5M shares, which represents about 5.3% of the company's float of 198.27M shares.

10. Denny's Corporation (DENN): Engages in the ownership and operation of a chain of family-style restaurants. Market cap at $418.25M, most recent closing price at $4.35. The stock is currently trading 3.07% above its 20-day moving average, 6.25% above its 50-day MA, and 11.99% above its 200-day MA. Net institutional purchases in the current quarter at 4.8M shares, which represents about 5.05% of the company's float of 95.06M shares.

*Institutional data sourced from Fidelity, all other data sourced from Finviz.

Source: 10 Rallying Stocks Under $5 Being Bought Up By Hedge Funds